抗胆碱能/镇静药物负担与阿尔茨海默病风险老年人的主观认知下降
调整共病和多重用药后,DBI可预测SCD严重程度,且存在DBI与年龄交互,65岁及以上者药物负担越高SCD越重。
要点
- 抗胆碱能/镇静药物负担可预测阿尔茨海默病风险老年人的主观认知下降严重程度。
- DBI与年龄存在交互,65岁及以上人群中药物负担越高SCD越重。
- 年龄单独不是SCD的预测因素,需关注药物暴露而非仅年龄。
核心结论
- 在65岁及以上有阿尔茨海默病风险的成人中,抗胆碱能/镇静药物暴露与更严重的主观认知下降相关。
研究设计与样本
- 42%为载脂蛋白ε4携带者,78%有阿尔茨海默病家族史。
- 用单一问题评估主观认知下降,DBI根据自我报告的用药方案和老年人剂量推荐计算。
主要发现
- 主观认知下降和抗胆碱能/镇静药物负担均较普遍。
- 调整共病和多重用药后,药物负担越高越能预测主观认知下降严重程度,而年龄单独无预测作用。
- DBI与年龄存在显著交互,65岁及以上个体中药物负担越高主观认知下降越严重。
关键数值与推荐
- 主观认知下降用单一问题「Do you feel like your memory is becoming worse?」评估,选项为「No」「Yes, but this does not worry me」「Yes, this worries me」。
- DBI根据自我报告的用药方案和老年人剂量推荐计算。
- 在年龄均值±1 SD处检验年龄对DBI与SCD关联的调节效应。
临床怎么用
- 对65岁及以上有阿尔茨海默病风险的老年人,应评估抗胆碱能/镇静药物负担(DBI)。
- 药物负担较高者可能需关注主观认知下降,考虑优化用药。
- 纵向研究尚需验证该关联是否为神经退行性疾病的临床前标志。
局限性
- 研究为横断面设计,无法确定因果关系。
- 主观认知下降用单一问题评估。
- DBI基于自我报告的用药方案。
- 样本为社区居住、英语 speaking、有阿尔茨海默病风险的老年人,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticholinergic/sedative drug use, measured by the Drug Burden Index (DBI), has been linked to cognitive impairment in older adults. Subjective cognitive decline (SCD) may be among the first symptoms patients with Alzheimer's disease (AD) experience. We examined whether DBI values are associated with SCD in older adults at risk of AD. We hypothesized that increased DBI would be associated with greater SCD at older ages. METHOD: Two-hundred-six community-dwelling, English-speaking adults (age = 65 ± 9 years) at risk of AD (42% apolipoprotein ε4 carriers; 78% with AD family history) were administered a single question to ascertain SCD: "Do you feel like your memory is becoming worse?" Response options were "No"; "Yes, but this does not worry me"; and "Yes, this worries me." DBI values were derived from self-reported medication regimens using older adult dosing recommendations. Adjusting for relevant covariates (comorbidities and polypharmacy), we examined independent effects of age and DBI on SCD, as well as the moderating effect of age on the DBI-SCD association at mean ± 1 SD of age. RESULTS: Both SCD and anticholinergic/sedative drug burden were prevalent. Greater drug burden was predictive of SCD severity, but age alone was not. A significant DBI*Age interaction emerged with greater drug burden corresponding to more severe SCD among individuals age 65 and older. CONCLUSION: Anticholinergic/sedative drug exposure was associated with greater SCD in adults 65 and older at risk for AD. Longitudinal research is needed to understand if this relationship is a pre-clinical marker of neurodegenerative disease and predictive of future cognitive decline.
引用
- Margolis SA, Kelly DA, Daiello LA, et al. Anticholinergic/Sedative Drug Burden and Subjective Cognitive Decline in Older Adults at Risk of Alzheimer's Disease. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32886748. doi:10.1093/gerona/glaa222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。